We therefore propose that CRELD2 is a potential druggable target in osteoclast precursors which could modulate osteoclast differentiation and osteolysis in diseases characterised by defective osteoclast differentiation and/or function such as osteopetrosis and osteoporosis. Here, CRELD2 is linked to osteoporosis.